271 related articles for article (PubMed ID: 15491997)
1. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.
Ho M; Kreitman RJ; Onda M; Pastan I
J Biol Chem; 2005 Jan; 280(1):607-17. PubMed ID: 15491997
[TBL] [Abstract][Full Text] [Related]
2. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
3. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
[TBL] [Abstract][Full Text] [Related]
4. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.
Decker T; Oelsner M; Kreitman RJ; Salvatore G; Wang QC; Pastan I; Peschel C; Licht T
Blood; 2004 Apr; 103(7):2718-26. PubMed ID: 14525789
[TBL] [Abstract][Full Text] [Related]
5. Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment.
Krauss J; Arndt MA; Martin AC; Liu H; Rybak SM
Protein Eng; 2003 Oct; 16(10):753-9. PubMed ID: 14600205
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
7. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Mansfield E; Amlot P; Pastan I; FitzGerald DJ
Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
[TBL] [Abstract][Full Text] [Related]
8. Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma.
Arndt MA; Krauss J; Schwarzenbacher R; Vu BK; Greene S; Rybak SM
Int J Cancer; 2003 Dec; 107(5):822-9. PubMed ID: 14566834
[TBL] [Abstract][Full Text] [Related]
9. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
10. The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.
Kawa S; Onda M; Ho M; Kreitman RJ; Bera TK; Pastan I
MAbs; 2011; 3(5):479-86. PubMed ID: 22048691
[TBL] [Abstract][Full Text] [Related]
11. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
12. Improving antibody affinity by mimicking somatic hypermutation in vitro.
Chowdhury PS; Pastan I
Nat Biotechnol; 1999 Jun; 17(6):568-72. PubMed ID: 10385321
[TBL] [Abstract][Full Text] [Related]
13. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
Kreitman RJ; Wang QC; FitzGerald DJ; Pastan I
Int J Cancer; 1999 Mar; 81(1):148-55. PubMed ID: 10077166
[TBL] [Abstract][Full Text] [Related]
14. Recombinant immunotoxins for treating cancer.
FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
[TBL] [Abstract][Full Text] [Related]
15. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
Weldon JE; Xiang L; Chertov O; Margulies I; Kreitman RJ; FitzGerald DJ; Pastan I
Blood; 2009 Apr; 113(16):3792-800. PubMed ID: 18988862
[TBL] [Abstract][Full Text] [Related]
16. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.
Krauss J; Arndt MA; Vu BK; Newton DL; Seeber S; Rybak SM
Biochem Biophys Res Commun; 2005 Jun; 331(2):595-602. PubMed ID: 15850802
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW
Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328
[TBL] [Abstract][Full Text] [Related]
18. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
Pop LM; Liu X; Ghetie V; Vitetta ES
Int Immunopharmacol; 2005 Jul; 5(7-8):1279-90. PubMed ID: 15914332
[TBL] [Abstract][Full Text] [Related]
19. Improvement of anti-Burkholderia mouse monoclonal antibody from various phage-displayed single-chain antibody libraries.
Kim HS; Lo SC; Wear DJ; Stojadinovic A; Weina PJ; Izadjoo MJ
J Immunol Methods; 2011 Sep; 372(1-2):146-61. PubMed ID: 21787781
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
